Join to View Full Profile
8000 Ravines Edge CtSte 200Columbus, OH 43235
Phone+1 614-304-3444
Fax+1 614-304-3433
Dr. Boster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganResidency, Neurology, 2003 - 2006- University of MichiganInternship, Internal Medicine, 2002 - 2003
University of Cincinnati College of MedicineClass of 2002
Certifications & Licensure
TN State Medical License 2023 - 2027
IL State Medical License 2023 - 2026
KY State Medical License 2023 - 2026
MI State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
WV State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
American Board of Psychiatry and Neurology Neurology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Combination Therapy Using Cellcept and Rebif in RRMS Start of enrollment: 2006 Aug 01
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis Start of enrollment: 2011 Mar 01
- Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump Start of enrollment: 2012 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 36 citationsToward Precision Phenotyping of Multiple Sclerosis.David Pitt, Chih Hung Lo, Susan A Gauthier, Richard A Hickman, Erin Longbrake
Neurology(R) Neuroimmunology & Neuroinflammation. 2022-11-01 - 13 citationsAutoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass
Multiple Sclerosis. 2022-04-01 - 35 citationsEfficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial:Alasdair Coles, Douglas L. Arnold, Ann D Bass, Aaron Boster, D Alastair S Compston
Therapeutic Advances in Neurological Disorders. 2021-04-23
Press Mentions
- Diagnosing MS During a Pandemic: UK vs. USOctober 23rd, 2020
Neurologists Turn to Telemedicine During Coronavirus ShelteringApril 3rd, 2020
Hospital Plots Leadership Path in MS ResearchSeptember 8th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
